logo
logo

Iksuda Therapeutics Closes $47 Million Financing Round

Jun 07, 2021•about 4 years ago

Amount Raised

$47 Million

Newcastle

Description

Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

Company Information

Company

Iksuda Therapeutics

Location

Newcastle, Washington, United States

About

Iksuda is an emerging biotechnology company focused on developing antibody-based therapies for the treatment of cancer as well as broader based therapeutics. Our main goal is to develop effective therapies to improve patients’ lives. Our mission is to enable improved clinical regimes through cre ...

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech